Cetuximab Combined With Pembrolizumab or Finotonlimab and Chemotherapy in R/M HNSCC

This is an open-label, randomized, prospective, multicenter phase III trial to evaluate the efficacy and safety of the combination therapy of cetuximab with either pembrolizumab or finotonlimab, alongside chemotherapy, as a first-line treatment, compared with pembrolizumab or finotonlimab with chemotherapy for R/M HNSCC.

NCT Number	NCT07509099
Lead Sponsor	Ji Dongmei
Conditions	Squamous Cell Carcinoma of Head and Neck
Enrollment	316 participants
Start Date	2026-04-01
Primary Completion	2030-09-30 (estimated)
Study Completion	2030-09-30 (estimated)
Updated on ClinicalTrials.gov	2026-04-03